Calcium Density as a Marker of Coronary Plaque Stabilization in Primary Prevention

Q: What is the clinical evidence from this study?

Study design: RCT. Population: Asymptomatic intermediate cardiovascular risk (n=338). Intervention: Statin treatment (primary prevention strategy) vs. Usual care. Primary outcome: Per-lesion level change in volumes of calcified plaque subtypes (β = 0.89 for intermediate-density calcium, β = 0.79 for high-density calcium, β = -9.83 for noncalcified plaque, p=0.02, 0.001, and <0.001 respectively).

Q: What does this research mean for the field?

In asymptomatic intermediate-risk individuals, statin therapy is associated with regression of noncalcified plaque and a shift toward intermediate- and high-density coronary calcification, reflecting plaque stabilization. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

Q: What question did this study set out to answer?

To examine whether statin therapy promotes coronary plaque stabilization in asymptomatic individuals by shifting coronary plaque toward higher-density calcified subtypes over 3 years.

Sheran A. Vasanthakumar; Stephen James Nicholls; Nitesh Nerlekar; Thomas Hugh Marwick; Andrew Lin

doi:10.1016/j.jcmg.2026.07.029

October 1, 2026JACC. Cardiovascular imagingOpen Access

Calcium Density as a Marker of Coronary Plaque Stabilization in Primary Prevention

View Full Paper

Ask AI

Bookmark

Share

Key result

Statin therapy linked to progression of dense calcium alongside regression of noncalcified plaque.

β = 0.89 for intermediate-density calcium, β = 0.79 for high-density calcium, β = -9.83 for noncalcified plaque
P 0.02, 0.001, and <0.001 respectively
n=338

Why the study?

Despite primary prevention statin treatment, a substantial proportion of individuals remain at residual risk for cardiovascular events, and the role of coronary plaque compositional changes as markers of stabilization is unclear.

Does statin treatment increase coronary calcified plaque density and volume in asymptomatic intermediate-risk individuals?

Key Points

To examine whether statin therapy promotes coronary plaque stabilization in asymptomatic individuals by shifting coronary plaque toward higher-density calcified subtypes over 3 years.
Post hoc analysis of the randomized CAUGHT-CAD trial (ACTRN12614001294640) comparing a statin-based primary prevention strategy against usual care in asymptomatic, statin-naive, intermediate-risk individuals undergoing serial coronary CTA at baseline and 3 years.
Quantified 840 coronary lesions from 338 participants (mean age 58.3 ± 6.9 years, 57.1% men, 161 statin-treated) across 5 subtypes: noncalcified (≤350 HU), low-density (351-500 HU), intermediate-density (501-700 HU), high-density (701-1000 HU), and very high density (>1,000 HU) calcium.
Statin treatment was significantly associated with noncalcified plaque regression (β = -9.83, SE = 1.64; P < 0.001) alongside progression in intermediate-density (β = 0.89, SE = 0.39; P = 0.02) and high-density (β = 0.79, SE = 0.24; P = 0.001) calcium after adjusting for risk factors and baseline plaque volume.
Among statin-treated participants, achieving an LDL-C reduction ≥30% was associated with greater progression of high-density (β = 1.11, SE = 0.49; P = 0.03) and very high density (β = 1.68, SE = 0.85; P = 0.04) calcium.

Study Design

Type

RCT (n=338)

Randomization

Randomized

Structured PICO

Does statin treatment increase coronary calcified plaque density and volume in asymptomatic intermediate-risk individuals?

P

Population

338 asymptomatic, statin-naive, intermediate-risk individuals followed for 3 years with serial coronary computed tomographic angiography.

I

Intervention

Primary prevention strategy including statin treatment

C

Comparator

Usual care

O

Outcome

Per-lesion level change in volumes of calcified plaque subtypes at 3 yearssurrogate

Main Result

Effect estimate: β = 0.89 for intermediate-density calcium, β = 0.79 for high-density calcium, β = -9.83 for noncalcified plaque

p-value: p=0.02, 0.001, and <0.001 respectively

Limitations

Post hoc analysis
post hoc analysis

Implication

Statin therapy in asymptomatic intermediate-risk individuals is associated with a shift toward higher density calcium and regression of noncalcified volume within coronary plaques, suggesting plaque stabilization.

Abstract

BACKGROUND: Despite primary prevention statin treatment, a substantial proportion of individuals remain at residual risk for cardiovascular events. Coronary computed tomographic angiography (CTA) enables the quantification of compositional changes in calcified plaque. OBJECTIVES: The aim of this study was to examine whether increases in coronary calcified plaque volume and density associated with statin therapy could be used as a marker of plaque stabilization in asymptomatic individuals undergoing serial coronary CTA. METHODS: In the CAUGHT-CAD trial, asymptomatic, statin-naive, intermediate-risk individuals were randomized to a primary prevention strategy (including statin treatment) vs usual care. Participants underwent coronary CTA at baseline and 3 years. In this post hoc analysis, volumes of 5 plaque subtypes were quantified: noncalcified (≤350 HU), low-density calcium (351-500 HU), intermediate-density calcium (501-700 HU), high-density calcium (701-1000 HU), and very high density calcium (>1,000 HU). The primary outcome was the per-lesion level change in volumes of calcified plaque subtypes. RESULTS: Eight hundred forty lesions were included from 338 participants (mean age: 58.3 ± 6.9 years, 57.1% men, 161 [47.6%] statin treated). Statin treatment was associated with greater progression in intermediate-density (β = 0.89, SE = 0.39; P = 0.02) and high-density (β = 0.79, SE = 0.24; P = 0.001) calcium, alongside regression of noncalcified plaque (β = -9.83, SE = 1.64; P < 0.001), following adjustment for cardiovascular risk factors, low-density lipoprotein cholesterol (LDL-C) level, and baseline plaque volume. Among statin-treated participants, LDL-C reduction ≥30% was associated with greater progression of high-density (β = 1.11, SE = 0.49; P = 0.03) and very high density (β = 1.68, SE = 0.85; P = 0.04) calcium. CONCLUSIONS: In asymptomatic, intermediate-risk individuals, statin treatment was associated with a shift toward higher density calcium within coronary plaques, most marked with effective lowering of LDL-C. (Coronary Artery Calcium Score: Use to Guide Management of Hereditary Coronary Artery Disease [CAUGHT-CAD]; ACTRN12614001294640).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Vasanthakumar et al. (2026) conducted an RCT in Asymptomatic intermediate cardiovascular risk (n=338). Statin treatment (primary prevention strategy) vs. Usual care was evaluated on Per-lesion level change in volumes of calcified plaque subtypes (β = 0.89 for intermediate-density calcium, β = 0.79 for high-density calcium, β = -9.83 for noncalcified plaque, p=0.02, 0.001, and <0.001 respectively). Statin treatment was associated with greater progression in intermediate-density (P=0.02) and high-density calcium (P=0.001), and regression of noncalcified plaque (P<0.001).

synapsesocial.com/papers/6ad2191afc66cec880534f00 https://doi.org/10.1016/j.jcmg.2026.07.029

View Full Paper

Ask AI

Bookmark

Share

Calcium Density as a Marker of Coronary Plaque Stabilization in Primary Prevention

Key Points

Study Design

Structured PICO

Main Result

Limitations

Implication

Abstract

Discussion

Cite This Study

Calcium Density as a Marker of Coronary Plaque Stabilization in Primary Prevention

Key Points

Study Design

Structured PICO

Main Result

Limitations

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from JACC. Cardiovascular imaging

Keep reading

More related papers

More from JACC. Cardiovascular imaging